Lanreotide
approvedAlso known as: Somatuline, BIM 23014
**Mechanism of Action** Lanreotide is a synthetic somatostatin analog with high affinity for somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5). By binding to these receptors, it inhibits the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), as well as various neuroendocrine hormones (e.g., serotonin, gastrin, glucagon). Its depot formulation provides sustained release, enabling prolonged suppression of hormonal activity in conditions such as acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). **Key Research Findings** Clinical trials (e.g., the ELECT and CLARINET studies) demonstrated that lanreotide effectively normalizes GH and IGF-1 levels in acromegaly patients and significantly prolongs progression-free survival in patients with well-differentiated, non-functioning GEP-NETs. Pharmacokinetic data confirm stable drug concentrations over 28 days with monthly intramuscular injections. Adverse effects are typically mild and include gastrointestinal disturbances, gallstones, and transient injection-site reactions. **Clinical Relevance** Lanreotide is a first-line therapy for acromegaly and a standard treatment for unresectable or metastatic GEP-NETs. Its long-acting formulation improves patient compliance compared to daily injections. Ongoing research explores its utility in other neuroendocrine tumors and polycystic liver disease. For research purposes only — not medical advice.
Key data
C54H69N11O10S2Research & studies
Octreotide showed a strong association with necrotizing enterocolitis in neonates.; Pasireotide was significantly linked to acute pancreatitis and glucose metabolism disorders.; Elevated risks of liver and biliary tract infections were identified for somatostatin analogs.; Gastrointestinal and hepatobiliary adverse events were prominent across all three drugs.
Frequently asked questions
What is Lanreotide?
**Mechanism of Action** Lanreotide is a synthetic somatostatin analog with high affinity for somatostatin receptor subtypes 2 (SSTR2) and 5 (SSTR5). By binding to these receptors, it inhibits the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), as well as various neuroendocrine hormones (e.g.,
How does Lanreotide work?
Depot somatostatin analog inhibiting GH/IGF-1 and neuroendocrine secretion; approved for acromegaly and GEP-NETs.
What is the research status of Lanreotide?
Lanreotide is currently classified as approved, with 1,219 research references on record. This is for research purposes only and is not medical advice.
What is the molecular weight of Lanreotide?
Lanreotide has a molecular weight of approximately 1096.3 g/mol (formula C54H69N11O10S2).
Related peptides
Long-acting somatostatin analog that inhibits GH, glucagon, and gut hormone secretion; used for acromegaly and neuroendocrine tumors.
Recombinant PTH(1-34) that, given intermittently, stimulates osteoblastic bone formation; approved for severe osteoporosis.
36-aa HIV gp41 fusion inhibitor that blocks viral entry into CD4 cells; first-in-class antiretroviral fusion inhibitor.
Selective bradykinin B2 receptor antagonist decapeptide approved for acute attacks of hereditary angioedema.
PTHrP(1-34) analog that selectively favors bone anabolism with less hypercalcemia than teriparatide; approved for osteoporosis.
Build on Lanreotide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key